ChatGPTを活用して業務のAI化を進めています。プロンプトエンジニアリングの専門家です！と、名乗れるレベルではありませんが、かなり色々使いこなしてきています。この１年、病気で失われた能力は、別な能力を発達させる、進化することで生き残っていこうと思います。
<><><>
<>
24/04/27
[HTML] Mendelian randomisation highlights type 1 diabetes as a causal determinant of idiopathic pulmonary fibrosis
X Ma, Y Zhang, F Wu, X Liu, W Zhang - Diabetology & Metabolic Syndrome, 2024
… It is unclear whether type 1 diabetes (T1D) causes idiopathic pulmonary fibrosis (IPF), despite observational research linking the two conditions. Therefore, our study aimed to examine the causal link between T1D and the likelihood of IPF by …
[HTML] Downregulation of HMGCS2 mediated AECIIs lipid metabolic alteration promotes pulmonary fibrosis by activating fibroblasts
J Yang, X Pan, M Xu, Y Li, C Liang, L Liu, Z Li, L Wang… - Respiratory Research, 2024
… Abnormal lipid metabolism has recently been reported as a crucial signature of idiopathicpulmonary fibrosis (IPF). However, the origin … Idiopathic pulmonary fibrosis (IPF), the most common and well-characterized form of pulmonary fibrosis, is …
- HMGCS2媒介AECII脂質代謝変化の下方制御は線維芽細胞を活性化することにより肺線維症を促進する
Body weight loss is a simple and useful indicator of prognosis and predictive tolerability in the first year of nintedanib therapy in patients with interstitial lung disease
H Yamakawa, S Sato, H Ohta, K Kusano, R Kawabe… - Respiratory Investigation, 2024
… Subjects included 67 patients with idiopathicpulmonary fibrosis (IPF) and 76 with non-IPFprogressive fibrosing-ILD including fibrotic hypersensitivity pneumonitis (n = 16), unclassifiable (n = 35), connective tissue disease-ILD (n = 21), and nonspecific …
- 体重減少は、間質性肺疾患患者におけるニンテダニブ治療の 1 年目の予後および予測忍容性の単純かつ有用な指標
Mimosa pudica L. extract ameliorates pulmonary fibrosis via modulation of MAPK signaling pathways and FOXO3 stabilization
QC Nguyen, HA Nguyen, TA Pham, VTH Tran… - Journal of …, 2024
… Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing pulmonary disorder that has a poor prognosis and high mortality. Although … A pathological characteristic of IPF is excessive accumulation of extracellular matrix (ECM) …
- Mimosa pudica L. 抽出物は、MAPK シグナル伝達経路の調節と FOXO3 の安定化を介して肺線維症を改善
E038 Predictors for pulmonary function decline in interstitial lung disease
S Eisa, S Rabbani, A Podlasek, S Sankar, S Audet… - Rheumatology, 2024
… We included most common conditions in the analysis: idiopathic pulmonary fibrosis (IPF) = 65, RA = 22, idiopathic pulmonary fibrosiswith autoimmune features (IPAF) =15, hypersensitivity pneumonitis (HP) = 20, unclassified=25, SSc-ILD = 13, Sjogren’s …
- 間質性肺疾患における肺機能低下の予測因子
Interstitial lung diseases associated with ANCA positivity: a different disease spectrum from interstitial pneumonia with autoimmune features
W Zhu, C Zhou, X Sun, P Xue, Z Li, W Zhang, J Zhao… - Respiratory Medicine and …, 2024
… of ANCA-positive idiopathic pulmonaryfibrosis (IPF) was mostly compared with ANCA-negative IPF, suggesting that these two diseases have a similar prognosis, although a few studies indicate that ANCA-positive IPF might bring a worse …
- ANCA陽性に関連する間質性肺疾患：自己免疫特徴を伴う間質性肺炎とは異なる疾患スペクトル
[HTML] Chimeric Antigen Receptor T-Cell Therapy for Refractory Post-transplant Lymphoproliferative Disorder after Lung Transplantation
K Veit, T Pena, J Klesney-Tait, E Mou, U Farooq - JHLT Open, 2024
… We report the use of CAR-T for treating refractory PTLD in a 73-year-old female who was 7 years post bilateral lung transplantation for idiopathic pulmonary fibrosis (IPF). We discuss the immunosuppression management in this patient, as well as her …
- 肺移植後の難治性移植後リンパ増殖性疾患に対するキメラ抗原受容体T細胞療法
Research progress of PD-L1 in inflammatory lung diseases
AG Li, AH Cai, HJ Li, QY Huang, YS Tu - Sheng li xue bao:[Acta physiologica Sinica], 2024
… This article reviews the research progress and potential clinical value of PD-L1 in inflammatory lung diseases, including acute lung injury, chronic obstructive pulmonary disease, asthma and idiopathic pulmonary fibrosis. … Idiopathic …
- 炎症性肺疾患におけるPD-L1の研究の進歩
24/04/26
[PDF] Exploring therapeutic targets for molecular therapy of idiopathic pulmonary fibrosis
Y Li, C Jiang, W Zhu, S Lu, H Yu, L Meng - Science Progress, 2024
… Moreover, pulmonary fibrosis was also found as a COVID-19 complication. Currently, two … IPF are becoming increasingly available. This article reviews the research platform, including cell and animal models involved in molecular therapy …
- 特発性肺線維症の分子治療の治療標的の探索
Inhibition of TGF-β/Smad signaling attenuates extracellular matrix accumulation in a human ex-vivo model of pulmonary fibrosis
M Riley - 2024
… Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by accumulation of scar tissue and decreased lung … corroborate that modulation of TGF-β activity using SB431542 inhibitor has a therapeutic potential for …
[PDF] Comparative Pharmacokinetics and Safety Assessment of 1st‐and 2nd‐Generation Zinpentraxin Alfa Drug Products in Healthy Volunteers: A Randomized Crossover …
TH Mai, R Yadav, A Arjomandi, C Jung, MM Meier… - Clinical Pharmacology in …, 2024
… Idiopathic pulmonary fibrosis (IPF) is a chronic disease characterized by fibrosis and the … The currently approved treatments for IPFmay slow the disease progression and increase life … for drugs and interventions that can further slow …
- 健康なボランティアにおける第 1 世代および第 2 世代のジンペントラキシン アルファ医薬品の比較薬物動態および安全性評価: ランダム化クロスオーバー研究
Treatment of Interstitial Lung Disease in Systemic Sclerosis
M Elhai, B Crestani, MS Muraru-Carbrune, Y Allanore - … : From Pathogenesis to …, 2024
… with idiopathic interstitial pneumonia and patients with idiopathic pulmonary fibrosis in subgroup analysis. Interestingly, there was a reduced number of progression events in patients receiving inhaled treprostinil as compared to those …
- 全身性硬化症における間質性肺疾患の治療
Clinical Assessment of Pulmonary Hypertension
SM Hon, B Lechartier, M Humbert, HW Farber - Scleroderma: From Pathogenesis to …, 2024
… Distinguishing PAH from PH due to pulmonary fibrosis is often difficult, especially since some patients can have both pulmonaryfibrosis … Following the 2015 ESC/ERS PH guidelines [6], treatment of patients with SSc-PAH should follow the same …
- 肺高血圧症の臨床評価
24/04/25
[HTML] Idiopathic pulmonary fibrosis (IPF): Diagnostic routes using novel biomarkers
K Bartold, Z Iskierko, PS Sharma, HY Lin, W Kutner - Biomedical Journal, 2024
… and partial recovery from diseases like COVID-19, while others, the idiopathicinterstitial pneumonia (IIP) cases, have no identifiable cause [5]. Idiopathic pulmonaryfibrosis (IPF) is a pulmonary fibrosis of origin that remains unknown. It is …
- 特発性肺線維症 (IPF): 新規バイオマーカーを使用した診断ルート
[HTML] Novel kinase 1 regulates CD8+ T cells as a potential therapeutic mechanism for idiopathic pulmonary fibrosis
ZY Tan, Y Lou, YC Qin, W Lin, BB Liang, SR Sooranna… - International Journal of …, 2024
… Idiopathic pulmonary fibrosis (IPF) is a rare, … from IPF patients. By utilizing bioinformatics techniques, we identified crucial disease-related genes and their biological functions, and characterized their expression patterns. Furthermore, we …
- 新規キナーゼ 1 は特発性肺線維症の潜在的な治療機構として CD8+ T 細胞を制御
[PDF] The incidence of acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis
Z Ji, B Xu, S Li, Y Xie - 2024
… Background: Idiopathic pulmonary brosis (IPF) is a chronic interstitial lung disease with a … in patients with IPF, hoping to provide reference for the prevention and management of IPF. … incidence of AE-IPF, hoping to provide reference for the …
- 特発性肺線維症の急性増悪の発生率:系統的レビューとメタ分析
[HTML] Elevations in NLR at the first year of pirfenidone treatment may be associated with worse prognosis in patients with idiopathic pulmonary fibrosis
Ö Özdemir, G Polat, FD Üçsular, DS Unat, S Ermin… - The Egyptian Journal of …, 2024
… Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease of lungs typically occurring in smoking males over the age of 50. … thirty-seven IPF patients were screened for the study. A total of 125 patients with the diagnosis of idiopathic …
- ピルフェニドン治療の初年度におけるNLRの上昇は、特発性肺線維症患者の予後不良と関連している可能性がある
[PDF] MULTIDISCIPLINARY APPROACH IN THE DIAGNOSIS OF IDIOPATHIC NONSPECIFIC INTERSTITIAL PNEUMONIA
SM Shukhratovich - FAN, TA'LIM, MADANIYAT VA INNOVATSIYA JURNALI …, 2024
… Idiopathic interstitial pneumonia (IIP) is a group of lung diseases of unknown origin, the most common clinical manifestation of which is … formation of widespread pulmonary fibrosis, “honeycomb” lung, etc. This group includes …
- 特発性非特異的間質性肺炎の診断における多分野のアプローチ
SEMA3B inhibits TGFβ-induced extracellular matrix protein production and its reduced levels are associated with a decline in lung function in IPF
DJK Yombo, S Ghandikota, CP Vemulapalli, P Singh… - American Journal of …, 2024
… This study unveils an anti‐ 41 fibrotic role for Semaphorin class 3B (SEMA3B) in the pathogenesis of idiopathic pulmonary fibrosis42 (IPF). … This study investigated the role of SEMA3B signaling in the pathogenesis of idiopathic 94 pulmonary fibrosis …
- SEMA3B は TGFβ 誘導性の細胞外マトリックスタンパク質の産生を阻害し、そのレベルの低下は IPF における肺機能の低下と関連しています。
Interstitial Lung Disease: A Review
TM Maher - JAMA, 2024
… OBSERVATIONS The most common forms of ILD are idiopathic pulmonary fibrosis (IPF), which accounts for approximately one-third of all cases of ILD, hypersensitivity pneumonitis, accounting for 15% of ILD cases, and connective …
- 間質性肺疾患：総説
Protective effects of microbial biosurfactants produced by Bacillus halotolerans and Candida parapsilosis on bleomycin-induced pulmonary fibrosis in mice: Impact of …
AM Mousa, MU Nooman, SS Abbas, SM Gebril… - Toxicology and Applied …, 2024
… Idiopathic pulmonary fibrosis (IPF) is an irreversible disease which considered the most fatal pulmonary fibrosis. Pulmonary toxicity including IPF is the most severe adverse effect of bleomycin, the chemotherapeutic agent. Based on the fact that …
- マウスのブレオマイシン誘発肺線維症に対するバチルス・ハロトレランスおよびカンジダ・パラプシロシスによって産生される微生物バイオサーファクタントの保護効果：TGF-β1/Smad-3経路およびmiRNA-326を介した抗酸化作用、抗炎症作用および抗線維化作用の影響
[PDF] Cell competition drives bronchiolization and pulmonary fibrosis.
SP De Langhe, R Warren, K Klinkhammer, H Lyu… - 2024
… Idiopathic pulmonary fibrosis (IPF) is a progressive scarring disease arising from the maladaptive differentiation of lung stem cells into bronchial epithelial cells rather than into alveolar type 1 (AT1) cells, which are responsible for gas exchange. Here …
- 細胞の競合は細気管支形成と肺線維症を引き起こします。
[PDF] Targeting glutamate metabolism in chronic lung diseases
Z Guo, F Yan - Clinical and Translational Discovery, 2024
… Chronic lung diseases such as chronic obstructive pulmonary disease (COPD), asthma and idiopathic pulmonary fibrosis pose significant global health challenges and demand effective treatment solutions due to the substantial burden they impose …
24/04/23
[HTML] Identification of shared molecular mechanisms and diagnostic biomarkers between heart failure and idiopathic pulmonary fibrosis
P Zhang, L Geng, K Zhang, D Liu, M Wei, Z Jiang, Y Lu… - Heliyon, 2024
… Heart failure (HF) and idiopathic pulmonaryfibrosis (IPF) are global public health concerns. The relationship between HF and IPF is widely … Idiopathic pulmonary fibrosis (IPF) is a long-lasting and advancing lung illness that involves the …
- 心不全と特発性肺線維症の間で共通する分子機構と診断用バイオマーカーの同定
[PDF] Elucidating the pathway activity and prognostic significance of diverse cell-death patterns in idiopathic pulmonary fibrosis
J Sun, Y Sun, H Guo, Y Nie, S Zhou, Y Zeng - 2024
… Idiopathic pulmonary brosis (IPF) is one of the interstitial lung … Idiopathic pulmonary brosis (IPF) is a chronic interstitial lung disease characterized by progressive and irreversible brosis of the lung parenchyma. (1) This brosis leads to …
- 特発性肺線維症における多様な細胞死パターンの経路活性と予後的重要性の解明
24/04/23
[HTML] Identification of shared molecular mechanisms and diagnostic biomarkers between heart failure and idiopathic pulmonary fibrosis
P Zhang, L Geng, K Zhang, D Liu, M Wei, Z Jiang, Y Lu… - Heliyon, 2024
… Heart failure (HF) and idiopathic pulmonaryfibrosis (IPF) are global public health concerns. The relationship between HF and IPF is widely … Idiopathic pulmonary fibrosis (IPF) is a long-lasting and advancing lung illness that involves the …
- 心不全と特発性肺線維症の間で共通する分子機構と診断用バイオマーカーの同定
[PDF] Elucidating the pathway activity and prognostic significance of diverse cell-death patterns in idiopathic pulmonary fibrosis
J Sun, Y Sun, H Guo, Y Nie, S Zhou, Y Zeng - 2024
… Idiopathic pulmonary brosis (IPF) is one of the interstitial lung … Idiopathic pulmonary brosis (IPF) is a chronic interstitial lung disease characterized by progressive and irreversible brosis of the lung parenchyma. (1) This brosis leads to …
- 特発性肺線維症における多様な細胞死パターンの経路活性と予後的重要性の解明
24/04/22
Mendelian Randomization revealed a one-way causal association between increased Isovalerylcarnitine (C5) levels and the risk of idiopathic pulmonary fibrosis
J He, H Chen, J Fu, Y Hua, J Guo - 2024
Background There have been multiple observational studies that have established a link between metabolite levels in the body and idiopathic pulmonary fibrosis (IPF), specifically focusing on metabolites derived from fatty acids. However, a complete …
- メンデルランダム化により、イソバレリルカルニチン（C5）レベルの上昇と特発性肺線維症のリスクとの間の一方向の因果関係が明らかになった
[PDF] Detection of interstitial lung disease in rheumatoid arthritis: diagnostic tests and prognostic value
BK Sofíudóttir - 2024
… Other studies have found that a thickened and fragmented visceral pleura was sensitive in sub-pleural fibrosis on HRCT in SSc-ILD and idiopathic pulmonary fibrosis [56, 57]. However, the applicability of TUS to identify clinically relevant and …
- 関節リウマチにおける間質性肺疾患の検出: 診断検査と予後値
24/04/21
[HTML] Role of transient receptor potential ankyrin 1 in idiopathic pulmonary fibrosis: modulation of M2 macrophage polarization
Y Yang, Z Xiao, W Yang, Y Sun, X Sui, X Lin, X Yang… - Cellular and Molecular Life …, 2024
… Idiopathic pulmonary fibrosis (IPF) poses significant challenges due to limited treatment options despite its complex pathogenesis … macrophage polarization in IPF progression, potentially offering novel therapeutic targets. Using a bleomycin-induced …
- 特発性肺線維症における一過性受容体電位アンキリン 1 の役割: M2 マクロファージ極性化の調節
[HTML] lncRNA-mRNA Co-Expression and Regulation Analysis in Lung Fibroblasts from Idiopathic Pulmonary Fibrosis
A López-Martínez, JC Santos-Álvarez… - Non-Coding RNA, 2024
… Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease marked by abnormal accumulation of extracellular matrix (ECM) due to … -coding RNAs (lncRNAs) and messenger RNAs (mRNAs) in IPF fibroblasts. The meta-analysis unveiled 584 …
- 特発性肺線維症の肺線維芽細胞における lncRNA-mRNA の共発現および制御解析
Differences in Healthcare Utilization at the End of Life: a Comparison Study of Three Progressive Lung Diseases
A Suen, KE Bischoff, A Kotwal, R Sudore, E Farrand - Journal of Pain and Symptom …, 2024
… Our findings suggestpossible unmet palliative care needs in patients dying with COPD or IPF. Abstract. Patients with lung cancer (LC), idiopathic pulmonary fibrosis (IPF), or chronic obstructive pul- monary disease (COPD) frequently report high symp- tom …
- 終末期における医療利用の違い: 3 つの進行性肺疾患の比較研究
WNK2 regulates the chondrocyte response to hyperosmotic stress
S Veerabhadraiah, D Matheson, M Honeggar, C Aslor… - Osteoarthritis and Cartilage, 2024
… The top pathways upregulated by WNK2 overexpression and sorbitol treatment are microRNA biogenesis, IL17 signaling, and RAC signaling, while CREB signaling, pulmonaryfibrosis idiopathic signaling, and Notch signaling. This response is …
- WNK2は高浸透圧ストレスに対する軟骨細胞の反応を調節する
[PDF] Correlation of Clinical, Hematological, Radiological and Spirometric Profile among Interstitial Lung Disease Patients Presenting To Tertiary Care Centre
VC RP, S Sasikumar, SG Sowmitha, G Vadivelu - NATURALISTA CAMPANO, 2024
… Sarcoidosis may afflict people of various ages and ethnicities, although idiopathic pulmonaryfibrosis (IPF) is more common in older folks [6]. … pneumonia known as idiopathic pulmonaryfibrosis (IPF) is one of the best researched ILD subtypes. On …
- 三次医療センターを受診する間質性肺疾患患者間の臨床的、血液学的、放射線学的、肺活量測定プロファイルの相関関係
<>
<><><>
特発性肺線維症( idiopathic pulmonary fibrosis (IPF) )関連の学術的情報収集してシェアしています。Google Scholar SearchのUpdateを定期的に掲載しています。GoogleのAIが一定の重み付けはしているとは思いますが、玉石混交です。
当面、毎週アラートの内容をアップしていこうと思います。
###
